Scarica l'app Stockscreener
2.06
1.48%
0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NMRA Giù?
Forum
Previsione
Neumora Therapeutics Inc Borsa (NMRA) Ultime notizie
In the mix post-Ventyx, more NLRP3s to seize? - BioWorld News
Neumora Therapeutics (NMRA) Is Among the Best Penny Stocks Set to Explode - Insider Monkey
If You Invested $1,000 in Neumora Therapeutics Inc (NMRA) - Stock Titan
Neumora Therapeutics (NMRA) price target increased by 19.25% to 9.33 - MSN
Rally Mode: Is Neumora Therapeutics Inc forming a breakout patternInflation Watch & Growth Oriented Trade Recommendations - baoquankhu1.vn
Short Squeeze: Does Neumora Therapeutics Inc stock have upside surprise potentialEarnings Summary Report & Community Consensus Stock Picks - baoquankhu1.vn
H.C. Wainwright Sticks to Its Buy Rating for Neumora Therapeutics, Inc. (NMRA) - The Globe and Mail
Neumora tops Q4 earnings forecasts as pipeline advances, shares slip - MSN
Neumora Therapeutics management to join Needham Healthcare Conference fireside chat April 13 - Traders Union
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) - The Globe and Mail
Financial intelligence spearheads cross-departmental progress at Neumora Therapeutics - Traders Union
Q2 EPS Forecast for Neumora Therapeutics Boosted by Analyst - MarketBeat
ARCH funds detail Neumora (NASDAQ: NMRA) ownership near 19% stake - Stock Titan
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the ... - Bluefield Daily Telegraph
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX) - The Globe and Mail
Neumora Therapeutics, Inc. (NMRA) Gets a Buy from Guggenheim - The Globe and Mail
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Neumora Therapeutics Maps High-Stakes Catalyst Road Ahead - TipRanks
Loss Report: Will Neumora Therapeutics Inc benefit from geopolitical trendsQuarterly Market Summary & Trade Opportunity Analysis - baoquankhu1.vn
Guggenheim Reaffirms "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $6 to $18 - Moomoo
Neumora Therapeutics' (NMRA) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Neumora Therapeutics, Inc. Common Stock Q4 2025 Earnings Call Summary - Yahoo Finance
Neumora Therapeutics Warns Nasdaq Delisting Risk Could Hit Liquidity, Share Price, and Capital Access - TipRanks
Neumora Therapeutics Inc (NMRA) Q4 2025 Earnings Call Highlights: Strong Financial Position ... By GuruFocus - Investing.com Canada
Neumora beats Q4 earnings expectations amid pipeline progress, stock falls 2% By Investing.com - Investing.com India
Guggenheim reiterates Neumora stock rating on pipeline progress By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Neumora Therapeutic (NMRA.US) will release its earnings report before the market opens on March 30. - Moomoo
Neumora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Neumora Therapeutics: Downgrading After Navacaprant Development Setback (NASDAQ:NMRA) - Seeking Alpha
Neumora Therapeutics 2025 Financial Update - AlphaStreet
Neumora Therapeutics Reports Strong 2025 Financials and Clinical Pipeline Progress Including NMRA-511 Alzheimer’s Agitation Data and KOASTAL-2/3 Enrollment 123 - Minichart
Stifel reiterates Neumora Therapeutics stock Hold rating at $3 By Investing.com - ca.investing.com
Neumora Therapeutics Sees Unusually Large Options Volume (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Neumora 2025 10-K Report: Precision Neuroscience, Intellectual Property, and Business Overview - Minichart
Earnings call transcript: Neumora Therapeutics beats Q4 2025 EPS forecast, stock dips By Investing.com - Investing.com South Africa
Neumora Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Neumora Therapeutics beats Q4 2025 EPS forecast, stock dips - Investing.com
Neumora Therapeutics Q4 Earnings Call Highlights - MarketBeat
Neumora beats Q4 earnings expectations amid pipeline progress, stock falls 2% - Investing.com Australia
Neumora Therapeutics, Inc. (NMRA) Q4 FY2025 earnings call transcript - Yahoo Finance
Neumora Therapeutics (NASDAQ:NMRA) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Neumora (NASDAQ: NMRA) maps key 2026–27 milestones for depression, Alzheimer’s and obesity drugs - Stock Titan
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget
Neumora (NMRA) posts 2025 loss, advances CNS pipeline with key 2026–27 milestones - Stock Titan
Neumora Therapeutics (NMRA) price target decreased by 16.15% to 7.82 - MSN
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):